Urinary tract infections (UTIs) are common, and widespread antibiotic resistance has led to urgent calls for new ways to combat them. Researchers at University of California, San Diego School of Medicine and Skaggs School ...
Apr 30, 2015
0
17
(HealthDay)—The first generic versions of the atypical antipsychotic drug Abilify (aripiprazole) have been approved by the U.S. Food and Drug Administration to treat schizophrenia or bipolar disorder.
Apr 30, 2015
0
8
Government policies that support UK pharmaceutical science and enhance export income are costing the NHS millions and undermine the National Institute for Health and Care Excellence. In an essay published today by the Journal ...
Apr 29, 2015
0
9
A new study released today found that drugs used to treat multiple sclerosis have soared in price in the past two decades, in some cases more than 700 percent, even though newer drugs have come to the market - a process that ...
Apr 24, 2015
0
499
(HealthDay)—The first U.S. generic version of Copaxone (glatiramer acetate injection) has been approved by the Food and Drug Administration to treat multiple sclerosis.
Apr 17, 2015
0
2
A generic version of insulin, the lifesaving diabetes drug used by 6 million people in the United States, has never been available in this country because drug companies have made incremental improvements that kept insulin ...
Mar 18, 2015
4
146
(HealthDay)—The first generic version of the heartburn drug Nexium (esomeprazole) has been approved by the U.S. Food and Drug Administration.
Jan 26, 2015
0
6
The system that allows patients rapid access to expensive new treatments lacks transparency and penalises small and low-income countries unable to negotiate lower prices with pharmaceutical manufacturers. Writing in the Journal ...
Dec 8, 2014
0
0
An examination of the potential interaction between pharmaceutical companies and the U.S. Food and Drug Administration (FDA) to discuss future studies finds that one-quarter of recent new drug approvals occurred without any ...
Nov 25, 2014
0
0
Development of new drugs for treatment of disease is an expensive, time-consuming and labour-intensive effort for both pharmaceutical companies and academics. For the past 15 years, "cost per approval" of new drugs has increased ...
Oct 28, 2014
0
0
